Ergebnisse der Tätigkeit des Nationalen Referenzzentrums für Staphylokokken im Jahr 1998

Braulke, Ch.; Heuck, D; Witte, Wolfgang

doi:10.1007/978-3-662-38283-7_83

Cited by 2 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The streptogramin B resistance determinants vgbA and vgbB were amplified using primers vgbA1 (5Ј-CCA GAT TCA GCA CCC TAC G) and vgbA2 (5Ј-CCC CCC ATT CAG TAA ACC), as well as vgbB1 (5Ј-CAG CAG TCT AGA TCA GAG TGG) and vgbB2 (5Ј-CAT ACG GAT CCA TCT TTT CC) (1,6). For erm genes the primers were used as described previously (9,19). The PCR mixture consisted of ca.…”

Section: Bacterial Isolatesmentioning

confidence: 99%

Methicillin-Resistant, Quinupristin-Dalfopristin-Resistant Staphylococcus aureus with Reduced Sensitivity to Glycopeptides

et al. 2001

View full text Add to dashboard Cite

Of 3,052 Staphylococcus aureus strains collected by the European SENTRY surveillance study, 35 were found to be nonsusceptible to quinupristin-dalfopristin (MIC of >2 mg/liter). These isolates originated from four hospitals in France and one in Spain. In isolates from two Parisian hospitals exhibiting the same SmaI macrorestriction pattern, streptogramin resistance was based on vatA and vgbA. One isolate from a hospital in Lyon and 22 from a hospital in Lille were of the vatB vgaB streptogramin A resistance genotype and possessed ermA and/or ermC. As deduced from the loss of either streptogramin A or streptogramin B resistance determinants in particular isolates, resistance to quinupristin-dalfopristin requires mechanisms conferring resistance to both compounds. The SmaI macrorestriction patterns of strains from hospitals in Lille and Lyon were different; however, similarity analysis suggested a relatedness of 20 methicillin-resistant S. aureus strains from the Lille hospital, a finding confirmed by PCR typing based on three different genomic polymorphisms. These groups of isolates were found to be hetero-glycopeptide-intermediate susceptible S. aureus. Information about the failure of glycopeptide chemotherapy has not been available.Methicillin-resistant Staphylococcus aureus (MRSA) has become an important nosocomial pathogen in many countries. Glycopeptides have been the drugs of choice for treating MRSA infections. However, with the emergence of intermediate susceptibility to glycopeptides, first reported from sporadic cases in many countries (12, 20) and more recently also from an outbreak of infections (11), other treatment alternatives such as quinupristin-dalfopristin and linezolid have become important. Quinupristin-dalfopristin is a combination of streptogramin B and A compounds with a synergistic activity against most gram-positive bacteria (8,14).Resistance to the B component is mediated by methylation of 23S rRNA which confers macrolide-lincosamide-streptogramin B (MLS B ) resistance when the erm genes are expressed constitutively (7). A second mechanism is hydrolysis of the drug by a lactonase encoded by the vgbA and the vgbB genes, respectively (1, 6). Two kinds of mechanisms are known to mediate resistance to the A compound: inactivation of the drug by acetylation and efflux. In staphylococci, three acetyltransferase genes, vatA, vatB, and vatC (3, 4, 6) and two genes for efflux pumps (ABC porters), vgaA and vgaB (2, 5), have been described. These streptogramin A and B resistance genes are often located on the same plasmids (6).In this study we describe quinupristin-dalfopristin-resistant S. aureus strains collected during the course of the European SENTRY surveillance study in European countries (18). These strains were characterized in our laboratory with regard to streptogramin resistance genes, phenotypic resistance to other antibiotics, and genotype. MATERIALS AND METHODS Bacterial isolates.A total of 35 isolates of S. aureus exhibiting insensitivity to quinupristin-dalfopristin originated f...

show abstract

Section: Bacterial Isolatesmentioning

confidence: 99%

Methicillin-Resistant, Quinupristin-Dalfopristin-Resistant Staphylococcus aureus with Reduced Sensitivity to Glycopeptides

et al. 2001

View full text Add to dashboard Cite

show abstract

“…Chemotherapie [6]). Parallel dazu wird eine überregionale Verbreitung epidemischer MRSA registriert [3,8,9]. Es besteht die Frage, ob diese Entwicklung mehr durch die Verbreitung zwischen den Krankenhäusern begründet ist oder ob auch außerhalb der Krankenhäuser MRSA-Reservoire existieren, wie kürzlich aus den USA und aus Australien sowie von Altenheimen [10] …”

Section: Zur Mrsa-situation In Deutschlandunclassified

Tätigkeitsbericht des Nationalen Referenzzentrums für Staphylokokken im Jahr 1999

Witte¹,

Heuck²,

Braulke³

2000

Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschu

Self Cite

View full text Add to dashboard Cite

Ergebnisse der Tätigkeit des Nationalen Referenzzentrums für Staphylokokken im Jahr 1998

Cited by 2 publications

References 10 publications

Methicillin-Resistant, Quinupristin-Dalfopristin-Resistant Staphylococcus aureus with Reduced Sensitivity to Glycopeptides

Methicillin-Resistant, Quinupristin-Dalfopristin-Resistant Staphylococcus aureus with Reduced Sensitivity to Glycopeptides

Tätigkeitsbericht des Nationalen Referenzzentrums für Staphylokokken im Jahr 1999

Contact Info

Product

Resources

About